From the Department of Plastic and Reconstructive Surgery, University of South Florida, Morsani College of Medicine.
University of South Florida, Morsani College of Medicine.
Ann Plast Surg. 2024 Jun 1;92(6S Suppl 4):S437-S440. doi: 10.1097/SAP.0000000000003956.
Breast cancer-related lymphedema (BRCL) is a potential sequela of high-risk breast cancer treatment. Preventive treatment with immediate lymphatic reconstruction (ILR) at the time of axillary lymph node dissection (ALND) has emerged as the standard of care; however, there is relatively little known about factors that may contribute to procedural failure.
A retrospectively maintained, institutional review board-approved study followed patients who underwent ILR at the time of ALND at our tertiary care center between May 2018 and May 2023. Patients who presented for at least one follow-up visit in our multidisciplinary lymphedema clinic met the criteria for inclusion. Patients who developed lymphedema despite ILR and potential contributing factors were further explored.
349 patients underwent ILR at our institution between May 2018 and May 2023. 341 of these patients have presented for follow-up in our multidisciplinary lymphedema clinic. 32 (9.4%) patients developed lymphedema despite ILR. This cohort was significantly more likely to be obese (56% vs 35%, P = 0.04). Multivariate logistic regression demonstrates increased odds of procedural failure in patients with a body mass index (BMI) ≥30 kg/m2 (odds ratio 2.6 [1.2-5.5], P = 0.01).
These data comment upon our institutions outcomes following ILR. Patients who develop lymphedema despite ILR tend to have a higher BMI, with a significantly increased risk in patients with a BMI of 30 or greater. Consideration of these data is critical for preprocedural counseling and may support a BMI cutoff when considering candidacy for ILR going forward, as well as when optimizing failures for secondary lymphedema procedures.
乳腺癌相关淋巴水肿(BRCL)是高危乳腺癌治疗的潜在后遗症。在腋窝淋巴结清扫术(ALND)时进行即时淋巴重建(ILR)的预防性治疗已成为标准护理;然而,对于可能导致手术失败的因素知之甚少。
本研究回顾性地维护了一个机构审查委员会批准的研究,该研究随访了 2018 年 5 月至 2023 年 5 月期间在我们的三级护理中心接受 ALND 时进行 ILR 的患者。在我们的多学科淋巴水肿诊所至少进行一次随访的患者符合纳入标准。进一步探讨了发生 ILR 后仍出现淋巴水肿的患者及其潜在的促成因素。
2018 年 5 月至 2023 年 5 月期间,我院共 349 例患者行 ILR。其中 341 例患者在我院多学科淋巴水肿诊所接受了随访。尽管进行了 ILR,但仍有 32 例(9.4%)患者发生了淋巴水肿。该队列肥胖的可能性明显更高(56%比 35%,P=0.04)。多变量逻辑回归表明,BMI≥30kg/m2 的患者手术失败的几率增加(比值比 2.6[1.2-5.5],P=0.01)。
这些数据反映了我们机构在进行 ILR 后的结果。尽管进行了 ILR,但仍发生淋巴水肿的患者倾向于 BMI 较高,BMI 为 30 或更高的患者风险显著增加。在进行术前咨询时考虑这些数据至关重要,并且可能支持在考虑进行 ILR 候选资格时设定 BMI 截止值,以及在优化继发性淋巴水肿手术失败时。